At a glance
- Originator Eisai Co Ltd
- Class Antipsychotics; Piperazines
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 02 Jul 2001 No-Development-Reported for Psychotic disorders in Japan (Unknown route)
- 30 Sep 1997 Preclinical development for Psychotic disorders in Japan (Unknown route)